Delaware | 06-1123096 | |
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. employer
identification no.)
|
Page No. | |||
PART I | Financial Information | ||
Item 1
|
Financial Statements (Unaudited)
|
3 | |
Condensed Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012
|
3
|
||
Condensed Consolidated Statements of Operations for the Six Months Ended June 30, 2013 and 2012
|
5
|
||
Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2013 and 2012
|
6 | ||
|
|
||
Notes to Condensed Consolidated Financial Statements
|
7
|
||
Item 2
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
14 | |
|
|||
Item 3
|
Quantitative and Qualitative Disclosures about Market Risk
|
18 | |
Item 4
|
Controls and Procedures
|
18 | |
PART II
|
Other Information
|
||
Item 1
|
Legal Proceedings
|
19 | |
Item 5
|
Other Information
|
19 | |
Item 6
|
Exhibits
|
|
20 |
Signatures
|
21 |
June 30,
|
December 31,
|
|||||||
Assets
|
2013
|
2012
|
||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 6,022,405 | $ | 9,245,094 | ||||
Short-term investments
|
757,973 | 1,250,794 | ||||||
Accounts receivable, net of allowance
|
2,638,326 | 2,197,513 | ||||||
Inventories
|
3,449,327 | 3,543,325 | ||||||
Other current assets
|
610,720 | 612,082 | ||||||
Total current assets
|
13,478,751 | 16,848,808 | ||||||
Property and equipment:
|
||||||||
Leasehold improvements
|
311,320 | 311,320 | ||||||
Equipment at customers
|
3,564,803 | 3,407,836 | ||||||
Machinery and equipment
|
5,635,683 | 5,439,521 | ||||||
9,511,806 | 9,158,677 | |||||||
Accumulated depreciation and amortization
|
(6,854,108 | ) | (6,443,303 | ) | ||||
Property and equipment, net
|
2,657,698 | 2,715,374 | ||||||
Intangible and other assets, net
|
850,804 | 830,245 | ||||||
Total assets
|
$ | 16,987,253 | $ | 20,394,427 | ||||
June 30,
|
December 31,
|
|||||||
Liabilities and Stockholders' Equity
|
2013
|
2012
|
||||||
Current liabilities:
|
||||||||
Accounts payable
|
$ | 1,058,666 | $ | 1,906,327 | ||||
Accrued expenses
|
1,327,505 | 1,625,923 | ||||||
Current portion of long-term debt
|
— | 697,834 | ||||||
Total current liabilities
|
2,386,171 | 4,230,084 | ||||||
Deferred gain on sale and leaseback of property
|
562,833 | 630,152 | ||||||
Long-term debt less current portion
|
4,884,132 | 2,685,560 | ||||||
Total liabilities
|
7,833,136 | 7,545,796 | ||||||
Commitments and contingencies
|
— | — | ||||||
Stockholders' equity:
|
||||||||
Preferred stock, $.001 par value per share, 1,000,000
|
||||||||
shares authorized -
|
||||||||
Series A convertible preferred stock, 95,500 shares
|
||||||||
issued and outstanding, liquidation value of
|
||||||||
$11,018,756 at June 30, 2013
|
8,802,000 | 8,802,000 | ||||||
Series A exchangeable preferred stock, 54,500 shares
|
||||||||
issued and outstanding, liquidation value of
|
||||||||
$6,327,160 at June 30, 2013
|
5,135,640 | 5,135,640 | ||||||
Common stock, $.004 par value per share, 40,000,000
|
||||||||
shares authorized, 13,821,221 and 13,767,192 shares
|
||||||||
issued at June 30, 2013, and December 31, 2012,
|
||||||||
respectively, including shares held in treasury
|
55,285 | 55,069 | ||||||
Common stock held in treasury, at cost - 86,000 shares
|
(101,480 | ) | (101,480 | ) | ||||
Additional paid-in capital
|
12,550,043 | 12,023,721 | ||||||
Accumulated deficit
|
(17,287,371 | ) | (13,066,319 | ) | ||||
Total stockholders' equity
|
9,154,117 | 12,848,631 | ||||||
Total liabilities and stockholders' equity
|
$ | 16,987,253 | $ | 20,394,427 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||
Net sales
|
$ | 5,042,420 | $ | 5,198,300 | $ | 10,618,258 | $ | 10,607,119 | ||||||||
Cost of sales
|
3,124,411 | 3,015,656 | 6,475,267 | 6,389,401 | ||||||||||||
Gross profit
|
1,918,009 | 2,182,644 | 4,142,991 | 4,217,718 | ||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
1,029,533 | 949,704 | 2,082,393 | 1,839,821 | ||||||||||||
Selling, general and administrative
|
3,460,829 | 2,897,182 | 6,542,582 | 6,004,703 | ||||||||||||
4,490,362 | 3,846,886 | 8,624,975 | 7,844,524 | |||||||||||||
Operating loss
|
(2,572,353 | ) | (1,664,242 | ) | (4,481,984 | ) | (3,626,806 | ) | ||||||||
Interest expense
|
76,824 | 735 | 142,554 | 883 | ||||||||||||
Other expense (income)
|
(15,308 | ) | (15,368 | ) | (403,487 | ) | (31,988 | ) | ||||||||
Net loss
|
(2,633,869 | ) | (1,649,609 | ) | (4,221,051 | ) | (3,595,701 | ) | ||||||||
Preferred stock dividend accretion
|
298,333 | 278,332 | 591,534 | 551,877 | ||||||||||||
Net loss applicable to common stockholders
|
$ | (2,932,202 | ) | $ | (1,927,941 | ) | $ | (4,812,585 | ) | $ | (4,147,578 | ) | ||||
Per share basic and diluted loss applicable to
common stockholders:
|
$ | (0.22 | ) | $ | (0.15 | ) | $ | (0.36 | ) | $ | (0.31 | ) | ||||
Weighted average number of common shares outstanding:
|
||||||||||||||||
Basic and diluted
|
13,425,416 | 13,260,345 | 13,408,584 | 13,239,593 | ||||||||||||
Six Months Ended
|
||||||||
June 30,
|
||||||||
2013
|
2012
|
|||||||
OPERATING ACTIVITIES:
|
||||||||
Net loss
|
$ | (4,221,051 | ) | $ | (3,595,701 | ) | ||
Adjustments to reconcile net loss to net cash
|
||||||||
used in operating activities:
|
||||||||
Depreciation and amortization
|
576,964 | 501,892 | ||||||
Amortization of debt discount
|
32,617 | — | ||||||
Stock compensation
|
463,106 | 466,778 | ||||||
Cash received from demutualization of insurance provider
|
(396,156 | ) | — | |||||
Impaired capitalized costs
|
1,323 | 27,262 | ||||||
Amortization of gain on sale and leaseback of property
|
(67,319 | ) | (67,319 | ) | ||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(440,813 | ) | (461,182 | ) | ||||
Inventories
|
93,998 | (334,617 | ) | |||||
Other current assets
|
1,360 | (129,003 | ) | |||||
Accounts payable and accrued expenses
|
(1,124,079 | ) | (195,851 | ) | ||||
Net cash used in operating activities
|
(5,080,050 | ) | (3,787,741 | ) | ||||
INVESTING ACTIVITIES:
|
||||||||
Expenditures for property and equipment
|
(466,735 | ) | (964,510 | ) | ||||
Short-term investments
|
492,821 | (7,952 | ) | |||||
Cash received from demutualization of insurance provider
|
396,156 | — | ||||||
Purchase of intangible assets
|
(62,935 | ) | (39,390 | ) | ||||
Net cash provided by (used in) investing activities
|
359,307 | (1,011,852 | ) | |||||
FINANCING ACTIVITIES:
|
||||||||
Deferred financing costs
|
(11,500 | ) | — | |||||
Proceeds from long-term debt and warrants
|
1,500,000 | — | ||||||
Proceeds from issuance of common stock
|
9,554 | 10,741 | ||||||
Net cash provided by financing activities
|
1,498,054 | 10,741 | ||||||
Net change in cash and cash equivalents
|
(3,222,689 | ) | (4,788,852 | ) | ||||
Cash and cash equivalents, beginning of period
|
9,245,094 | 11,387,300 | ||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD
|
$ | 6,022,405 | $ | 6,598,448 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
|
||||||||
Cash paid during the period for interest
|
$ | 102,556 | $ | 883 | ||||
Accrued liability settled with common stock
|
$ | 22,000 | $ | — |
The outstanding balance of the bank term loan is as follows:
|
June 30,
|
December 31,
|
|||||||
2013
|
2012
|
|||||||
Balance of bank term loan
|
$ | 5,000,000 | $ | 3,500,000 | ||||
Debt discount
|
(115,868 | ) | (116,606 | ) | ||||
4,884,132 | 3,383,394 | |||||||
Current portion
|
— | 697,834 | ||||||
Long-term portion
|
$ | 4,884,132 | $ | 2,685,560 | ||||
June 30,
|
December 31,
|
|||||||
2013
|
2012
|
|||||||
Raw materials
|
$ | 2,577,333 | $ | 2,489,750 | ||||
Work in process
|
13,343 | 34,384 | ||||||
Finished goods
|
858,651 | 1,019,191 | ||||||
$ | 3,449,327 | $ | 3,543,325 |
June 30,
|
December 31,
|
|||||||
2013
|
2012
|
|||||||
Patents and other assets
|
$ | 809,608 | $ | 714,810 | ||||
Patents pending
|
308,266 | 348,256 | ||||||
Purchased technology
|
43,893 | 46,026 | ||||||
Deferred financing costs
|
159,431 | 147,931 | ||||||
1,321,198 | 1,257,023 | |||||||
Accumulated amortization
|
(470,394 | ) | (426,778 | ) | ||||
$ | 850,804 | $ | 830,245 | |||||
2014
|
$ | 76,800 | ||
2015
|
66,500 | |||
2016
|
46,500 | |||
2017
|
21,500 | |||
2018
|
19,900 | |||
Thereafter
|
183,700 | |||
$ | 414,900 | |||
·
|
Tissue oximetry monitoring products – includes sales of the FORE-SIGHT cerebral monitors, sensors, and accessories.
|
·
|
Traditional vital signs monitoring products – includes:
|
1)
|
Vital signs bedside monitors and accessories, incorporating various combinations of measurement parameters for both human and veterinary use. Parameters found in these monitors include the Company’s proprietary MAXNIBP non-invasive blood pressure, pulse oximetry, electro-cardiography, temperature, and capnography.
|
2)
|
Blood pressure measurement technology – includes sales to OEM manufacturers of the Company’s proprietary MAXNIBP non-invasive blood pressure technology, sold as a discrete module to be included in the OEM customers’ own multi-parameter monitors, and related license fees.
|
3)
|
Supplies and service – includes sales of neonatal intensive care supplies, including electrodes, skin temperature probes, and service repair.
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||
Net loss
|
$ | (2,633,869 | ) | $ | (1,649,609 | ) | $ | (4,221,051 | ) | $ | (3,595,701 | ) | ||||
Preferred stock dividend accretion
|
298,333 | 278,332 | 591,534 | 551,877 | ||||||||||||
Net loss applicable to common stockholders
|
$ | (2,932,202 | ) | $ | (1,927,941 | ) | $ | (4,812,585 | ) | $ | (4,147,578 | ) | ||||
Weighted-average shares outstanding, net
|
||||||||||||||||
of unvested restricted common shares -
|
||||||||||||||||
used to compute basic and diluted loss per
|
||||||||||||||||
share applicable to common stockholders
|
13,425,416 | 13,260,345 | 13,408,584 | 13,239,593 | ||||||||||||
Weighted-
|
Aggregate
|
Weighted-Average
|
||||||||||||||
Option
|
Average
|
Intrinsic
|
Contractual Life
|
|||||||||||||
Shares
|
Exercise Price
|
Value (1)
|
Remaining in Years
|
|||||||||||||
Outstanding at December 31, 2012
|
2,007,125 | $ | 2.25 | $ | 307,406 | 8.0 | ||||||||||
Granted
|
— | — | — | — | ||||||||||||
Cancelled
|
— | — | — | — | ||||||||||||
Exercised
|
— | — | — | — | ||||||||||||
Outstanding at June 30, 2013
|
2,007,125 | 2.25 | 18,726 | 7.5 | ||||||||||||
Exercisable at June 30, 2013
|
869,166 | $ | 2.36 | $ | 18,726 | 6.1 | ||||||||||
Vested and expected to vest at
|
||||||||||||||||
June 30, 2013
|
1,973,032 | $ | 2.25 | $ | 18,726 | 7.5 |
(1) |
The intrinsic value of a stock option is the amount by which the market value, as of the applicable date, of the underlying stock exceeds the option exercise price.
|
Six Months
|
Weighted-Average
|
|||||||
Ended
|
Grant Date
|
|||||||
June 30, 2013
|
Fair-Value
|
|||||||
Outstanding at beginning of period
|
320,476 | $ | 2.19 | |||||
Granted
|
37,266 | 1.61 | ||||||
Cancelled
|
— | — | ||||||
Vested
|
(57,142 | ) | 2.15 | |||||
Outstanding at end of period
|
300,600 | $ | 2.12 | |||||
Three Months
|
Three Months
|
|||||||||||||||
Ended
|
Ended
|
Increase /
|
%
|
|||||||||||||
June 30, 2013
|
June 30, 2012
|
(Decrease)
|
Change
|
|||||||||||||
Tissue Oximetry Monitoring
|
$ | 2,215 | $ | 1,930 | $ | 285 | 15% | |||||||||
Traditional Vital Signs Monitoring
|
2,827 | 3,268 | (441 | ) | (13%) | |||||||||||
$ | 5,042 | $ | 5,198 | $ | (156 | ) | (3%) | |||||||||
Domestic Sales
|
$ | 3,964 | $ | 3,834 | $ | 130 | 3% | |||||||||
International Sales
|
1,078 | 1,364 | (286 | ) | (21%) | |||||||||||
$ | 5,042 | $ | 5,198 | $ | (156 | ) | (3%) | |||||||||
Three Months
|
Three Months
|
|||||||||||||||
Ended
|
Ended
|
Increase /
|
%
|
|||||||||||||
June 30, 2013
|
June 30, 2012
|
(Decrease)
|
Change
|
|||||||||||||
Sensor Sales
|
$ | 1,944 | $ | 1,722 | $ | 222 | 13% | |||||||||
Monitors & Accessories
|
271 | 208 | 63 | 30% | ||||||||||||
$ | 2,215 | $ | 1,930 | $ | 285 | 15% | ||||||||||
Domestic Sales
|
$ | 1,692 | $ | 1,586 | $ | 106 | 7% | |||||||||
International Sales
|
523 | 344 | 179 | 52% | ||||||||||||
$ | 2,215 | $ | 1,930 | $ | 285 | 15% | ||||||||||
Six Months Ended
|
Six Months Ended
|
Increase /
|
%
|
|||||||||||||
June 30, 2013
|
June 30, 2012
|
(Decrease)
|
Change
|
|||||||||||||
Tissue Oximetry Monitoring
|
$ | 4,449 | $ | 3,634 | $ | 815 | 22% | |||||||||
Traditional Vital Signs Monitoring
|
6,169 | 6,973 | (804 | ) | (12%) | |||||||||||
$ | 10,618 | $ | 10,607 | $ | 11 | 0% | ||||||||||
Domestic Sales
|
$ | 8,189 | $ | 8,045 | $ | 144 | 2% | |||||||||
International Sales
|
2,429 | 2,562 | (133 | ) | (5%) | |||||||||||
$ | 10,618 | $ | 10,607 | $ | 11 | 0% |
Six Months Ended
|
Six Months Ended
|
Increase /
|
%
|
|||||||||||||
June 30, 2013
|
June 30, 2012
|
(Decrease)
|
Change
|
|||||||||||||
Sensor Sales
|
$ | 3,802 | $ | 3,168 | $ | 634 | 20% | |||||||||
Monitor and Accessories Sales
|
647 | 466 | 181 | 39% | ||||||||||||
$ | 4,449 | $ | 3,634 | $ | 815 | 22% | ||||||||||
Domestic Sales
|
$ | 3,485 | $ | 2,916 | $ | 569 | 20% | |||||||||
International Sales
|
964 | 718 | 246 | 34% | ||||||||||||
$ | 4,449 | $ | 3,634 | $ | 815 | 22% | ||||||||||
10.1
|
Employment Agreement with John K. Gamelin dated August 5, 2013
|
10.2
|
Employment Agreement with Paul Benni dated May 1, 2008
|
31.1
|
Certification pursuant to Rule 13a-14(a) of Thomas M. Patton, President and Chief Executive Officer
|
31.2
|
Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief Financial Officer
|
32.1
|
Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report of Thomas M. Patton,
President and Chief Executive Officer, and Jeffery A. Baird, Chief Financial Officer
|
101
|
Interactive data files pursuant to Rule 405 of Regulation S-T.
|
/s/ Thomas M. Patton |
Date: August 7, 2013
|
By: Thomas M. Patton
|
|
President and Chief Executive Officer | |
/s/ Jeffery A. Baird |
Date: August 7, 2013
|
By: Jeffery A. Baird
|
|
Chief Financial Officer | |
|
(i)
|
a reduction greater than five (5) percent in the aggregate in the Employee's base salary or benefits, other than an across-the-board reduction affecting substantially all members of senior management;
|
|
(ii)
|
a material reduction in the Employee's duties and significant responsibilities hereunder following the occurrence of a Change of Control, as defined in Section 1 O(b) hereof (not including reasonable changes in title or in corporate structure); or
|
(iii)
|
a material breach of this Agreement by the Company (which shall include a failure to make payments due hereunder); provided, in any such case, that (1) the Employee shall provide, pursuant to Section 17 hereof, a prior written notice specifying the reasons for his termination to the Company's Board of Directors within sixty (60) days after the initial existence of the condition, and give Company an opportunity to cure such condition (if curable), and (2) "Good Reason" shall exist only if the Company shall fail to cure such condition within thirty-one (31) days after its receipt of such prior written notice. In addition, until the actual Separation from Service, the Employee must remain willing and able to continue to perform services in accordance with the terms of this Agreement and the Employee must not be in breach of any of the Employee's obligations hereunder.
|
|
(1)
|
Payment of the Severance Payments shall commence as of the Employee's Separation from Service date, and shall continue thereafter in equal fixed installments over a six month period in accordance with the Company's standard payroll procedures and normal payroll dates then in effect.
|
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee's annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-
1 (b)(9)(iii)(A)), the excess shall not be paid as provided in (1), above, but instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee's Separation from Service date, without adjustment for the delay in payment.
|
|
(3)
|
In no event shall Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Severance Payments to a later date.
|
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately before the Termination provided however, that the Company may elect not to provide such healthcare benefit in the event that by doing so the Company would be subject to a penalty under any applicable laws or regulations.
|
|
(1)
|
Payment of the Change of Control Severance Payments shall commence as of the Employee's Separation from Service date, and shall continue thereafter in equal fixed installments over a one year period in accordance with the Company's standard payroll procedures and normal payroll dates then in effect.
|
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee's annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-
1 (b)(9)(iii)(A)), the excess shall not be paid as provided in (1), above, but
instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee's Separation from Service date, without adjustment for the delay in payment.
|
|
(3)
|
In no event shall Change of Control Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Change of Control Severance Payments to a later date.
|
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately prior to his Separation from Service for the period of the COBRA coverage or one year, whichever is shorter.
|
Section 11.
|
Confidential Information
|
Section 12.
|
Remedy
|
Section 13.
|
Inventions
|
Section 14.
|
Successors and Assigns
|
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c.
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d.
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|